Document is current
Any future updates will be listed below
-
Authors
Ritchlin, Christopher T. https://orcid.org/0000-0002-2602-1219
Coates, Laura C.
Mease, Philip J.
van der Heijde, Désirée
Song, Jiao
Jiang, Yusang
Shawi, May
Kollmeier, Alexa P.
Rahman, Proton
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
-
More Information
Article History
Received: 21 June 2022
Accepted: 18 November 2022
First Online: 10 January 2023
Declarations
:
: The study is being conducted in compliance with the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. The protocol will be approved by each site’s governing ethical body. Each study patient is required to have provided written informed consent prior to the conduct on any study-related procedures.
: Not applicable.
: CTR: Grant/research support from AbbVie, Amgen, and UCB; consulting fees from Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB; LCC: funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We acknowledge the support of the National Institute for Health Research Clinical Research Network (NIHR CRN); PJM: Grant/research support from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; DvH: Consulting fees from AbbVie, Bayer, Bristol Myers Squibb, Cyxone, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB; serves as the director of Imaging Rheumatology BV; JS, APK: Employees of Janssen Research & Development, LLC; own stock or stock options in Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary; YJ: Employee of Cytel, contracted to provide services to Janssen Research & Development, LLC; MS: Employee of Janssen Pharmaceutical Companies of Johnson & Johnson; owns stock or stock options in Johnson & Johnson; PR: Grant/research support from Janssen and Novartis; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB.
